Vaginal atrophy is a consequence of reduced estrogen in urogenital and pelvic tissue that results in a loss of vaginal elasticity, dryness, decreased lubrication, dyspareunia, and urinary symptoms.
As a synthetic estrogen analog, promestriene has two important attributes.
- Firstly, promestriene is very poorly absorbed from the **bleep** and does not affect systemic hormone levels or estrogen activity.
- Secondly, promestriene has demonstrated anti-atrophic activity in the genitourinary tract, which leads to significant improvement in symptoms associated with vaginal atrophy.
